文献速递血栓与止血白血病

基于拓扑替康的方案用于晚期眼内视网膜母细胞瘤的眼球挽救与视力保护

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.
PubMed 文献 · J Clin Oncol · 2016-10-31

27例双侧视网膜母细胞瘤患儿接受拓扑替康联合长春新碱、卡铂及局部治疗,10年外照射放疗累积发生率为5.9%(SE±3),无事件生存率为69.2%(SE±27.2),25例中19例(76%)单眼视力达20/40或更好,所有患者均存活。

要点

  • 拓扑替康联合长春新碱、卡铂及积极局部治疗对晚期视网膜母细胞瘤有效,可实现眼球挽救并保留视力。
  • 10年外照射放疗累积发生率为5.9%(SE±3),无事件生存率为69.2%(SE±27.2)。
  • 毒性包括血小板减少(275个疗程中41次,15%)、发热性中性粒细胞减少(10%)和3级腹泻(27例中9例)。

核心结论

  • 拓扑替康联合长春新碱、卡铂及积极局部治疗是晚期视网膜母细胞瘤的有效方案,可实现眼球挽救并保留视力。
  • 毒性可预期并通过适当支持治疗管理。

研究设计与样本

  • 27例双侧视网膜母细胞瘤患者(男性14例,中位年龄8.4个月)接受化疗:两个疗程拓扑替康联合长春新碱,随后交替给予卡铂联合长春新碱两个疗程和拓扑替康联合长春新碱一个疗程,可选球周卡铂。
  • 第2周期后应用局部治疗。
  • 无事件生存定义为避免外照射放疗和眼球摘除。

主要发现

  • 54眼中42眼为Reese-Ellsworth IV至V组,37眼为国际视网膜母细胞瘤分类C至E组。
  • 11眼行眼球摘除:1眼诊断时摘除,9眼疾病进展(其中3眼接受外照射放疗),1眼治疗完成后发生新生血管性青光眼。
  • 1例患者因第1疗程 prolonged infection 退出方案;26例患者(51眼)纳入分析。
  • 10年时外照射放疗累积发生率为5.9%(SE±3),无事件生存率为69.2%(SE±27.2)。
  • Reese-Ellsworth IV至V组眼眼球生存率为77.5%(SE±21.2);国际分类C至E组眼为74.3%(SE≥18.8)。

临床怎么用

  • 作者认为拓扑替康联合长春新碱、卡铂及积极局部治疗是晚期视网膜母细胞瘤的有效方案,可实现眼球挽救并保留视力。
  • 毒性可预期并通过适当支持治疗管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To evaluate topotecan-based therapy for advanced intraocular retinoblastoma. Patients and Methods Twenty-seven patients with bilateral retinoblastoma (male patients, n = 14; median age, 8.4 months) received chemotherapy: two courses of topotecan plus vincristine followed by three alternating administrations of carboplatin and vincristine for two courses and topotecan plus vincristine for one course, with optional periocular carboplatin. Focal therapy was applied after cycle 2. Event-free survival was defined as avoidance of external-beam radiotherapy (EBRT) and enucleation. Results Of 54 eyes, 42 were Reese-Ellsworth group IV to V, and 37 were International Classification of Retinoblastoma group C to E. Eleven eyes were enucleated: one at diagnosis, nine with progressive disease including three eyes treated with EBRT, and one that developed neovascular glaucoma after completion of therapy. One patient was removed from protocol with prolonged infection in course 1; 26 patients (51 eyes) were analyzed. At 10 years, cumulative incidence of EBRT was 5.9% (SE ± 3), and event-free survival was 69.2% (SE ± 27.2). Ocular survival for Reese-Ellsworth group IV to V eyes was 77.5% (SE ± 21.2); it was 74.3% (SE ≥ 18.8) for International Classification group C to E eyes. Vision testing (median age, 7 years; range, 5 to 10 years) documented 20/70 vision or better in one eye of 23 patients; 19 (76%) of 25 patients demonstrated 20/40 vision or better in one eye. All patients experienced thrombocytopenia (41 episodes in 275 courses; 15%). There were 29 episodes of febrile neutropenia (10%). Grade 3 diarrhea was present in nine of 27 patients, and one patient had an allergic reaction to carboplatin. All patients are alive at median follow-up 7.4 years (range, 2.7 to 10 years). Conclusion Topotecan combined with vincristine, carboplatin, and aggressive focal therapies is an effective regimen for the treatment of advanced retinoblastoma and results in globe salvage with vision. Toxicities were anticipated and managed with appropriate supportive care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Brennan RC, Qaddoumi I, Mao S, et al. Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol. 2016. PMID: 28034080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。